Benzinga | Jun 16, 2021 07:32AM EDT

Paratek Pharmaceuticals Announces Initiation of Phase 2b Study in Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium Abscessus Complex with NUZYRA

-- U.S.-Based Sites Ready to Begin Enrolling Patients, Placebo-Controlled Study Evaluating NUZYRA Efficacy at 12 Weeks of Treatment

-- Potential $1.0 Billion Addressable Market Opportunity in the U.S. Based on Company Estimates

-- Paratek Hosting Investor Webinar with Corporate Updates and Key Opinion Leader and Patient Advocate Presentations on NTM abscessus today, June 16, 2021 at 10:00am ET

-- Company Providing Update on the Expected Timing of the Second Procurement under the BARDA Project BioShield Agreement